We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America ConferenceSeptember 3-4, 2019
BIO Investor ForumOctober 22-23, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
Search BIO members.
Adopting foreign price controls would jeopardize access to new, innovative medicines for patients in need.
Resources for emerging growth biotech companies would be better used for science than compliance with Section 404(b), economists find.
Learn about the Hatch-Waxman Act and its role in balancing innovation and drug competition.
For the 340B Drug Discount Program to work properly and benefit low-income patients, reforms are needed. Our latest infographic shows why.
The Medicare Part D benefit program was created to ensure seniors have access to affordable prescription drugs.
BIO's response to "A Better Deal" proposals on drug pricing.
PDUFA provides greater consistency, certainty and predictability in the FDA's drug review programs.
Learn about how the Bayh-Dole Act benefits the U.S. economy, consumers & patients.
Importing medicines from abroad would threaten public health and do little to reduce prescription drug costs. Here's why...